Current Research:

CagriSema is a combination therapy that includes Cagrilintide, an amylin analog, and Semaglutide. Amylin is a hormone co-secreted with insulin that helps regulate glucose levels and suppress appetite. Cagrilintide mimics amylin’s effects, enhancing satiety and reducing food intake. By combining Cagrilintide with Semaglutide, CagriSema, researchers aim to provide a more rapid and comprehensive approach to menopausal fat belly loss by targeting multiple pathways involved in appetite regulation and glucose metabolism.

1 Gram Cagrillintide (1000mg) Blend With Semaglutide 1 Gram/1000mg  Research Peptides 

Contact us for the COA.